#!/usr/bin/env node

const fetch = require('node-fetch');
const path = require('path');

require('dotenv').config({ path: path.join(process.cwd(), '.env') });
require('dotenv').config({ path: path.join(process.cwd(), '.env.wordpress') });

const WPCOM_ACCESS_TOKEN = process.env.WPCOM_ACCESS_TOKEN;
const WPCOM_SITE_ID = process.env.WPCOM_SITE_ID;

if (!WPCOM_ACCESS_TOKEN || !WPCOM_SITE_ID) {
    throw new Error('WPCOM credentials not configured');
}

// The correct content extracted from the nested JSON
const correctArticle = {
  title: "Deep Dive: CRISPR's Potential to Transform Diabetes Treatment",
  excerpt: "This deep dive explores how CRISPR technology is poised to revolutionize diabetes management by potentially eliminating the need for daily insulin injections, analyzing breakthroughs, technical aspects, and market implications.",
  content: `<h2>EXECUTIVE SUMMARY</h2>
<p>The article from Wired highlights a groundbreaking development in the field of genetic engineering where CRISPR technology is being utilized to offer new hope for treating diabetes. This innovative approach has the potential to eliminate daily insulin injections by directly addressing the root causes of diabetes through precise gene editing. The breakthrough could have profound implications on patient quality of life and healthcare systems globally. However, significant hurdles remain in translating lab success into clinical applications due to regulatory approval processes and safety concerns.</p>
<p>CRISPR's efficacy in treating diabetes has been demonstrated in preclinical studies, showing promising results that could lead to a paradigm shift in the management of this chronic condition. This deep dive will explore how CRISPR works in the context of diabetes treatment, its technical challenges and limitations, market implications for healthcare providers and pharmaceutical companies, expert perspectives on the technology's potential, and an outlook on future developments.</p>

<h2>BACKGROUND & CONTEXT</h2>
<p>The discovery of insulin in 1921 by Frederick Banting and Charles Best was a monumental breakthrough that saved countless lives, transforming diabetes from a fatal disease to one that could be managed. Despite this, the daily struggle with insulin injections remains a significant burden for millions of people worldwide.</p>
<p>Genetic research over the decades has led to an understanding that diabetes is fundamentally linked to genetic factors affecting how the body produces or uses insulin. The advent of CRISPR technology in 2012 by Jennifer Doudna and Emmanuelle Charpentier provided a powerful tool for precise gene editing, opening new possibilities in treating not only diabetes but various other diseases.</p>
<p>Before CRISPR, gene therapy approaches were limited in precision and efficacy. The development of CRISPR has overcome these limitations through its ability to target specific genes with unparalleled accuracy. This breakthrough is particularly significant for genetic conditions like Type 1 Diabetes (T1D) where the immune system mistakenly destroys insulin-producing beta cells.</p>
<p>The economic implications of diabetes are substantial, with healthcare costs and lost productivity reaching billions annually. Advancements in CRISPR technology could reduce these financial burdens while significantly improving patient quality of life. Key players in this field include pharmaceutical giants like Novo Nordisk, Sanofi, and biotech startups such as Editas Medicine and Intellia Therapeutics, all vying for a position in the emerging gene therapy market.</p>

<h2>THE BREAKTHROUGH</h2>
<p>The breakthrough described involves using CRISPR to correct genetic mutations that cause Type 1 Diabetes (T1D). This is achieved through the use of CRISPR-Cas9, which acts as molecular scissors capable of cutting and modifying DNA sequences. Researchers have identified specific genes associated with T1D, such as those responsible for immune regulation and beta cell function.</p>
<p>CRISPR's application in diabetes treatment has shown promising results in preclinical models. Studies conducted on mice have demonstrated the ability to restore normal insulin production by editing these critical genes without causing off-target effects. This represents a significant improvement over previous gene therapy methods which often led to unintended mutations or failed to achieve long-term efficacy.</p>
<p>Compared to traditional treatments like daily insulin injections and immunosuppressive drugs, CRISPR offers the potential for a one-time intervention that permanently corrects the underlying genetic cause of diabetes. This could lead to a more sustainable healthcare model where patients require less frequent medical interventions and monitoring.</p>

<h2>TECHNICAL DEEP DIVE</h2>
<p>The technical mechanism behind CRISPR-Cas9 involves using guide RNAs that match the target DNA sequence, leading Cas9 enzymes to precisely cut the DNA at the desired location. Once a section of DNA is removed or altered, it can be replaced with corrected genetic material.</p>
<p>In the context of diabetes treatment, this means targeting genes associated with immune regulation and beta cell function. For instance, correcting mutations in autoimmune response genes could prevent the destruction of insulin-producing cells. Similarly, enhancing gene expression responsible for beta cell regeneration can potentially restore normal insulin production.</p>
<p>The process begins by isolating patient cells that are then edited ex vivo (outside the body). After ensuring safety and efficacy, these genetically modified cells are reintroduced into the patient's body through targeted delivery mechanisms such as viral vectors. This approach minimizes risks associated with directly editing genes within living tissue.</p>
<p>Challenges in this process include ensuring high precision to avoid off-target effects, optimizing cell delivery methods for efficient integration without adverse immune reactions, and developing scalable manufacturing processes that can produce these therapies cost-effectively on a large scale.</p>

<h2>MARKET & INDUSTRY IMPLICATIONS</h2>
<p>The potential impact of CRISPR-based diabetes treatments is profound. It could disrupt the current market dominated by insulin manufacturers and lead to new business models centered around genetic therapies. Companies specializing in gene editing technologies stand to benefit significantly if they can bring effective products to market before regulatory hurdles.</p>
<p>Pharmaceutical giants like Novo Nordisk, currently a leading player in diabetes treatment through insulin sales, face the prospect of reduced revenue from traditional treatments as CRISPR-based solutions gain traction. Conversely, biotech startups and specialized gene therapy companies could see substantial growth opportunities if they can demonstrate successful clinical outcomes.</p>
<p>Investment trends indicate growing interest in this sector with venture capitalists increasingly backing early-stage companies working on genetic therapies for diabetes. However, high development costs and long regulatory timelines present significant financial risks that investors must consider.</p>

<h2>EXPERT PERSPECTIVES</h2>
<p>Experts in the field view CRISPR's application in treating diabetes as both promising and challenging. Leading researchers emphasize its transformative potential while also acknowledging hurdles like ensuring safety, efficacy, and cost-effectiveness at scale.</p>
<p>"While the science is exciting, we must proceed with caution," says Dr. Emily Smith from the University of California, Berkeley. "Safety is paramount. We need rigorous testing to ensure that gene editing does not introduce new health risks."</p>
<p>Skeptics argue that despite positive preclinical results, translating these into human treatments remains fraught with uncertainties including ethical concerns about genetic modifications and long-term side effects.</p>
<p>Independent validation from multiple sources supports the scientific merit of CRISPR but also highlights the need for continued research to address outstanding questions regarding its clinical application.</p>

<h2>FUTURE IMPLICATIONS & TIMELINE</h2>
<p>Near-term (0-2 years): The focus will be on refining gene editing techniques and conducting more rigorous preclinical testing. Regulatory frameworks will also evolve to accommodate new technologies, though this process is likely to take time.</p>
<p>Medium-term (2-5 years): Clinical trials with human subjects could begin if preliminary safety data are satisfactory. Early adopters might include patients with severe forms of diabetes where the benefits outweigh risks.</p>
<p>Long-term (5-10 years): Widespread adoption may occur as more data accumulate on long-term efficacy and safety profiles. The healthcare ecosystem will adapt, potentially shifting focus from managing symptoms to curing diseases through gene editing.</p>
<p>Key milestones include securing regulatory approval for initial CRISPR-based therapies, achieving cost reductions in manufacturing processes, and conducting large-scale clinical trials that establish clear therapeutic benefits over existing treatments.</p>
<p>Potential obstacles include navigating complex ethical debates around genetic modification, overcoming technical limitations such as delivery mechanisms, and addressing economic barriers to widespread access.</p>

<h2>CONCLUSION</h2>
<p>The potential of CRISPR technology in transforming diabetes treatment represents a significant leap forward in healthcare innovation. By offering the possibility of curing rather than merely managing this chronic condition, it holds promise for dramatically improving patient outcomes and reducing societal burdens associated with long-term disease management.</p>
<p>While challenges remain, particularly around safety and regulation, the scientific community is cautiously optimistic about the future of CRISPR-based therapies. Continued investment in research and development will be crucial to realizing these transformative possibilities while addressing ethical considerations and ensuring equitable access for all patients.</p>`
};

async function fixPost() {
    console.log('üîß Fixing WordPress post ID 583...');
    console.log(`   New title: "${correctArticle.title}"`);

    const apiUrl = `https://public-api.wordpress.com/rest/v1.1/sites/${WPCOM_SITE_ID}/posts/583`;
    const response = await fetch(apiUrl, {
        method: 'POST',
        headers: {
            'Authorization': `Bearer ${WPCOM_ACCESS_TOKEN}`,
            'Content-Type': 'application/json'
        },
        body: JSON.stringify({
            title: correctArticle.title,
            content: correctArticle.content,
            excerpt: correctArticle.excerpt
        })
    });

    if (response.ok) {
        const result = await response.json();
        console.log('‚úÖ Post updated successfully!');
        console.log(`   URL: ${result.URL}`);
    } else {
        const error = await response.text();
        console.log(`‚ùå Update failed: ${response.status}`);
        console.log(error);
    }
}

fixPost().catch(console.error);
